The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...
Sodium-glucose cotransporter 2 (SGLT2) inhibition seems to reduce the progression of nonsevere aortic stenosis over 5 years, with a larger treatment effect seen in those who take the drugs the longest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results